Corey Ford explains why the rise of biosimilars and specialty therapies requires a shift from universal support models to highly tailored strategies.
Corey Ford
Advertisement
Corey Ford is the vice president of reimbursement and policy insights for AmerisourceBergen.
Articles by Corey Ford
Corey Ford, principal at Nuvera, explains how pharma is shifting focus from HCPs to patients in support programs and commercialization.
As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Report: GLP-1s, Oncology to Drive Drug Spending Surge in 2027
2
Why Packaging Is Now a Frontline Issue In Pharma Supply Chains
3
CMS Could Make Drug Price Negotiations Permanent - What it Means for Pharma
4
Pharma Pulse: Drug Pricing Pressure in Europe and the New DSV Air Route
5